GNFT.PA
Price:
$5.07
Market Cap:
$252.53M
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic ...[Read more]
Industry
Biotechnology
IPO Date
2006-12-19
Stock Exchange
EURONEXT
Ticker
GNFT.PA
According to Genfit S.A.’s latest financial reports and current stock price. The company's current PE Ratio is 13.70. This represents a change of -586.88% compared to the average of -2.81 of the last 4 quarters.
The mean historical PE Ratio of Genfit S.A. over the last ten years is -15.25. The current 13.70 PE Ratio has changed -9085.57% with respect to the historical average. Over the past ten years (40 quarters), GNFT.PA's PE Ratio was at its highest in in the June 2021 quarter at 3.91. The PE Ratio was at its lowest in in the September 2014 quarter at -55.21.
Average
-15.25
Median
-9.17
Minimum
-47.86
Maximum
2.87
Discovering the peaks and valleys of Genfit S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 260.53%
Maximum Annual PE Ratio = 2.87
Minimum Annual Increase = -389.44%
Minimum Annual PE Ratio = -47.86
Year | PE Ratio | Change |
---|---|---|
2023 | -6.09 | -26.72% |
2022 | -8.31 | -389.44% |
2021 | 2.87 | -287.33% |
2020 | -1.53 | -84.71% |
2019 | -10.02 | 47.37% |
2018 | -6.80 | -45.72% |
2017 | -12.53 | -23.83% |
2016 | -16.45 | -64.06% |
2015 | -45.76 | -4.39% |
2014 | -47.86 | 260.53% |
The current PE Ratio of Genfit S.A. (GNFT.PA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.84
5-year avg
-4.62
10-year avg
-15.25
Genfit S.A.’s PE Ratio is greater than Innate Pharma S.A. (-20.70), greater than Nanobiotix S.A. (-4.26), greater than DBV Technologies S.A. (-0.83), greater than Cellectis S.A. (-2.29), greater than Adocia SA (-2.62),
Company | PE Ratio | Market cap |
---|---|---|
-20.70 | $157.36M | |
-4.26 | $209.93M | |
-0.83 | $66.76M | |
-2.29 | $133.81M | |
-2.62 | $80.90M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genfit S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Genfit S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Genfit S.A.'s PE Ratio?
How is the PE Ratio calculated for Genfit S.A. (GNFT.PA)?
What is the highest PE Ratio for Genfit S.A. (GNFT.PA)?
What is the 3-year average PE Ratio for Genfit S.A. (GNFT.PA)?
What is the 5-year average PE Ratio for Genfit S.A. (GNFT.PA)?
How does the current PE Ratio for Genfit S.A. (GNFT.PA) compare to its historical average?